Coeptis Therapeutics Reports Revenue Growth and Increased Operating Expenses in Q2 2025

Coeptis Therapeutics Holdings, Inc. reported its financial results for the second quarter of 2025, revealing a significant increase in revenue and a notable rise in operating expenses compared to the same period last year. The company generated $200,681 in revenue for the three months ended June 30, 2025, compared to no revenue in the same quarter of 2024. For the first half of 2025, total revenue reached $263,555, marking a substantial shift as the company began to monetize its NexGenAI Affiliates Network platform. Despite this revenue growth, Coeptis reported a net loss of $4,334,586 for the quarter, compared to a loss of $3,035,345 in the prior year, reflecting increased operational costs.

The company's total operating expenses surged to $4,676,738 in the second quarter of 2025, up from $2,828,102 in the same quarter of 2024. This increase was primarily driven by higher professional services expenses related to consulting and legal fees associated with the company's merger activities. Research and development expenses decreased year-over-year, largely due to the termination of a shared services agreement with Deverra Therapeutics. The company’s accumulated deficit also grew, reaching $105,989,201 as of June 30, 2025.

In terms of strategic developments, Coeptis has been actively pursuing partnerships and acquisitions to enhance its product offerings. The company recently entered into a licensing agreement with Vy-Gen-Bio, Inc. for the exclusive worldwide development and commercialization rights to its GEAR™ cell therapy platform. Additionally, Coeptis acquired the NexGenAI Affiliates Network platform, which is expected to bolster its technology segment and generate revenue through digital marketing services. The company also reported a significant increase in its cash position, with cash and cash equivalents rising to $1,996,726 as of June 30, 2025, compared to $532,885 at the end of 2024.

Operationally, Coeptis has made strides in expanding its market presence. The company recorded customer deposits totaling $1,631,445, indicating growing interest in its services. The number of shares outstanding increased to 4,166,713 as of June 30, 2025, up from 2,116,191 at the end of 2024, reflecting ongoing capital-raising efforts. The company continues to focus on its biotechnology and technology segments, with plans to further develop its product pipeline and enhance operational capabilities.

Looking ahead, Coeptis remains optimistic about its growth trajectory, although management acknowledges the challenges of achieving profitability in the near term. The company plans to continue raising capital through equity transactions to support its operations and product development initiatives. As it navigates the complexities of the biopharmaceutical landscape, Coeptis is committed to advancing its innovative therapies and technologies to improve patient outcomes.